Articles tagged with: Perifosine
NewsFlash »
Perifosine Receives “Orphan Medicinal Product Designation” In Europe For Myeloma – On March 1, Aeterna Zentaris announced that it received a positive opinion for orphan medicinal product designation for perifosine for the treatment of multiple myeloma. Perifosine is currently being studied in a Phase 3 trial for myeloma. Orphan medicinal product designation, similar to orphan drug status in the U.S., encourages development of drugs for rare medical conditions. The status gives the drug’s developer assistance with the application for the approval of the drug, waived application fees, and up to ten years of market exclusivity in Europe, if approved for treatment. Perifosine has already been granted orphan drug status in the U.S. For more information, please see the press release on the Æterna Zentaris Web site.
ImmunoCellular Therapeutics To Receive Patent For ICT-69 – On March 2, ImmunoCellular Therapeutics, a biotechnology company that is developing immune-based therapies for cancer treatment, announced that it received a Notice of Allowance on its patent application for ICT-69, a monoclonal antibody that targets multiple myeloma and ovarian cancers. Generally, this notification means that a patent will be issued once the issue fee is paid. For more information, see the ImmunoCellular Therapeutics Web site.
Myeloma Awareness Month Teleconference Series – There are three more teleconferences in the International Myeloma Foundation (IMF) teleconference series celebrating March as Myeloma Awareness Month. Patients, family members, caregivers, and health care professionals are welcome to join. The teleconferences provide up-to-date information regarding multiple myeloma and are held each Friday during March at 7 p.m. EST. Each teleconference will include an hour-long presentation followed by a 30-minute Q&A session on education (March 12), research (March 19), and advocacy (March 26). Please see the IMF Web site for more information.
Living With Myeloma Conference – The Arizona Myeloma Network is hosting its fourth annual “Living With Myeloma” conference on March 27 from 8:30 a.m. to 4:30 p.m. at the Scottsdale Conference Center. Physicians and researchers, including Dr. Robert Kyle, Professor of Medicine at the Mayo Clinic, will be giving invited talks. Patients, family members, caregivers, physicians, researchers, and health care providers interested in myeloma are invited. The conference, including a continental breakfast and hot lunch, is free. Heath care professionals may receive 4.5 continuing medical education credits for attending. Space is limited for the conference, and those interested in attending are urged to register quickly. For registration and more information, visit the Arizona Myeloma Network Web Site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News»
Results from recent Phase 1/2 clinical trials show that a perifosine, Velcade (bortezomib) and dexamethasone (Decadron) combination treatment is safe and effective for relapsed and refractory multiple myeloma. Perifosine is an alkyl-phosphocholine compound that controls cell division, cell growth and cell death, and is currently investigated for the treatment of multiple myeloma. Researchers presented their findings on December 5 at the American Society of Hematology’s 51st Annual Meeting.
“Great meeting—lots of exciting new developments for multiple myeloma,” wrote Dr. Paul Richardson, lead researcher in the study, in an …
NewsFlash »
FDA Puts Perifosine On Fast Track For Treatment Of Multiple Myeloma – Perifosine (KRX-0401) has received priority for evaluation by the FDA as an anti-cancer agent in the treatment of relapsed/refractory myeloma through the Fast Track program. The Fast Track program expedites the review of new drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs. A Phase 3 clinical trial is planned for the end of the year to investigate the use of perifosine in combination with Velcade (bortezomib) and dexamethasone (Decadron). For more information, please see the Keryx Biopharmaceuticals press release.
Higher Rates Of Multiple Myeloma And Other Cancers Seen In Residents Near Landfill – Researchers for the Central Cancer Registry found significantly higher rates than expected of multiple myeloma and other cancers among residents living near the White Street Landfill and the former E. H. Glass dump site in Greensboro, North Carolina. The study observed that the rate of multiple myeloma from 1990 to 2006 was twice the expected rate. However, the researchers say that the number of myeloma cases is too small to draw any conclusions. The researchers also maintained that study results do not imply causation nor do they prove that living near the landfills causes health problems. Genetic factors and lifestyle choices could also account for the discrepancy. For more information, please see the Central Cancer Registry report.
Resources, Treatments Under Development»
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals / Aeterna Zentaris |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine (news articles) is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a key signal transduction pathway. Akt is particularly important in the development of cancers, impacting programmed cell death, cell growth, cell differentiation, and cell survival. High levels of activated Akt are frequently observed …
NewsFlash »
Perifosine Receives Orphan-Drug Designation – Keryx Biopharmaceuticals announced that perifosine has been designated an Orphan-Drug by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. This designation greatly improves the marketable opportunity of perifosine for Keryx. Keryx is also in an agreement with the FDA for a Special Protocol Assessment for a Phase 3 trial in relapsed multiple myeloma that is expected to begin by the end of 2009. For more information, please see the PRNewswire press release.
Coleman Foundation Grants Loyola $2 Million – On September 15 the Loyola University Medical Center received a $2 million grant from The Coleman Foundation. The grant will help pay for the renovation of Loyola’s bone marrow transplant unit. The bone marrow transplant unit renovation is included in a larger effort to complete an Oncology Acute Care Center at Loyola. For more information, please see the Medical News Today article.
University Of Iowa Cancer Biology Researchers Receive Federal Grant – The University of Iowa Department of Radiation Oncology received over $3.7 million in federal funding from five grants that will allow continued cancer research. Researchers in the Department of Radiation Oncology are looking to improve our understanding of health risks involving low dose radiation to patients and workers. For more information, please see The University of Iowa news release.
NewsFlash »
Give And Get Campaign Results – The Gap Give and Get Campaign, which benefited The Leukemia & Lymphoma Society (LLS), was held from July 30 to August 2. The Gap is donating 5 percent of its sales during this period to the LLS, raising a total of $500,000 to support blood cancer research. For more information, please visit the LLS Web site.
Royal Hospital In Oman Setting Up Stem Cell Bank And Transplantation Unit – The Royal Hospital in Oman is in the final stages of establishing a stem cell bank and a transplantation unit. The stem cell bank will be ready by the end of 2009, and the transplantation unit will be completed by September 2010. Currently, building modifications are under way to accommodate the stem cell bank. The equipment for the stem cell bank has been selected and will be installed once the building modifications are completed. For more information, please visit the Zawya article.
Keryx To Present Overview Of Leading Drug Candidates – On September 9 at 2:50 p.m., Keryx will present an overview of its leading drugs at the Rodman & Renshaw Annual Global Investment Conference in New York City. Ron Bentsur, Chief Executive Officer of Keryx, will give the presentation on the lead drug candidates perifosine (KRX-0401) and Zerenex (ferric citrate). Perifosine is currently in trials as an oral anti-cancer drug that affects the growth and death of multiple myeloma cells, while Zerenex is in trials as a treatment for elevated phosphate levels in patients with severe kidney disease. The presentation will be available live by audio webcast at the Keryx Web site. For more information, please visit the Keryx press release.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News»
The U.S. Food and Drug Administration has approved a Phase 3 clinical trial evaluating perifosine in relapsed and refractory multiple myeloma patients. Perifosine, also known as KRX-0401, is an oral anti-cancer agent being developed by Aeterna Zentaris and licensed in the U.S., Canada, and Mexico by Keryx Biopharmaceuticals.
The trial, entitled “A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib,” will evaluate the safety and efficacy of perifosine, compared to placebo, when …